Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q2 2025 · 10-Q
Revenue$0.00$0.00−100.0% vs Q2 2024 Net Income-$23.52M-$23.52MN/M vs Q2 2024 EPS Diluted-$0.61-$0.61N/M vs Q2 2024 Operating Income-$23,084,519N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$20,842,289N/M ended Jun 30, 2025 · filed Aug 12, 2025 · 43 d after period end